Inhibrx Biosciences is a high-risk, catalyst-driven biotech, with valuation hinging on the clinical success of ozekibart and ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions. Neither ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on September ...

Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. Lower interest rates aided the biotech bounceback, as many companies in the sector rely on a ...